COMPARE · Data as of August 14, 2026
ANIP vs ETON
Verdict: Side-by-side breakdown using the Bull Rankings model. ANIP scored 80.1, ETON scored 72.0 — ANIP leads.
Compare another set
ANIP
ANI Pharmaceuticals, Inc.
80.1
$76.54 · $1.8B
fundamentals as of
Score gap
8.1
ANIP leads
ETON
Eton Pharmaceuticals, Inc.
72
$58.86 · $1.7B
fundamentals as of
The model, pillar by pillar (0–100 each)
ANIP
stronger →← stronger
ETON
66
Qualityreturns · margins · balance sheet
76
94
Growthrevenue & earnings expansion
100
83
Valuevaluation vs sector peers
50
ETON is stronger on 2 of 3 pillars.
Fundamentals, head-to-head
ANIP
ETON
$173mC
FCF
$15mC-
+30.9%A
Rev
+81.5%A
1.05C
D/E
1.02C
16.7xA-
P/E
150.9xD
1.25B
PEG
1.40B
Winner per row is the stronger grade in our model; a tie or a missing value shows no highlight.
Valuation · DCF cross-check
ANIP
ETON
45% below
Price vs fair valuelower is cheaper
335% above
~-6%/yr
Growth the price implies10-yr FCF · lower = less priced in
~54%/yr
+59%
1-yr DCF upside
-83%
+82%
5-yr DCF upside
-77%
+120%
10-yr DCF upside
-65%
The DCF is a cross-check on intrinsic value, separate from the quality-growth score above.
Model signals
ANIP
No notable signals flagged.
ETON
Why this score
- Short track record
The companies
ANIPANI Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.8b. Down 23% from 52-week high of $99.50 — deep drawdown territory. Revenue growing +31% — in hypergrowth territory. 8 sell-side analysts rate this a Buy with a mean 1-yr target of $108.38 (implying +42% upside).
Moat
ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 160% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined. Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Trial-readout binary — late-stage clinical trials carry approve/reject outcomes that swing valuation 30%+; the equity is effectively a portfolio of these binary events, not a steady cash-flow business.
ETONEton Pharmaceuticals, Inc.
Why now
Drug Manufacturers - Specialty & Generic · market cap $1.7b. Trading near 52-week high of $59.79 — momentum setup, limited technical margin of safety. Revenue growing +81% — in hypergrowth territory. 3 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.33 (implying +6% upside).
Moat
Net margin 12% beats the market median by a meaningful margin — the company is keeping more of every revenue dollar than the average S&P constituent. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 116% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk
Trailing P/E 150.9x prices in sustained high growth — any quarter that disappoints triggers sharp re-rating. Trading within 2% of the 52-week high — limited technical margin of safety; a momentum reversal would test conviction. P/S 15.9x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Verdict — model-derived comparison
Generating verdict… typically 5–10 seconds
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Where ANIP and ETON diverge
On the headline score the gap is 8.1 points in favor of ANIP. They get there differently, though — each leads on a different pillar, so the better pick depends on which you weight.
- ValueANIP 82.8 · ETON 50.0ANIP +32.8
- QualityANIP 66.1 · ETON 75.6ETON +9.5
- GrowthANIP 93.8 · ETON 100.0ETON +6.2
Pillars run 0–100 against sector peers, so a score is a statement about a company relative to its own industry rather than to the other name here. A wide Value gap usually means the market already prices the difference in quality or growth — which is the trade-off this comparison comes down to.